The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients

Letermovir is the first approved drug for cytomegalovirus (CMV) infection prophylaxis in adult patients who are CMV positive undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Because CMV infection risk varies from patient to patient, we evaluated whether a risk-based strategy coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Sourisseau, Mathilde, Faure, Emmanuel, Béhal, Hélène, Chauvet, Paul, Srour, Micha, Capes, Antoine, Coiteux, Valérie, Magro, Léonardo, Alfandari, Serge, Alidjinou, Enagnon Kazali, Simon, Nicolas, Vuotto, Fanny, Karam, Micheline, Faure, Karine, Yakoub-Agha, Ibrahim, Beauvais, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986711/
https://www.ncbi.nlm.nih.gov/pubmed/36350752
http://dx.doi.org/10.1182/bloodadvances.2022008667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986711/
https://www.ncbi.nlm.nih.gov/pubmed/36350752
http://dx.doi.org/10.1182/bloodadvances.2022008667

Ejemplares similares